Evidence map›Paper›PMID 33572999›Full record

ArticleInternational journal of molecular sciences2021

Cancer-Targeted Controlled Delivery of Chemotherapeutic Anthracycline Derivatives Using Apoferritin Nanocage Carriers.

Katarzyna Kurzątkowska, Manuel A Pazos, Jason I Herschkowitz, Maria Hepel

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.International journal of molecular sciences · 2025
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Katarzyna KurzątkowskaDepartment of Chemistry, State University of New York at Potsdam, Potsdam, NY 13676, USA.ORCID 0000-0001-8996-3468
Manuel A PazosDepartment of Biomedical Sciences, Cancer Research Center, University at Albany, State University of New York, Rensselaer, NY 12222, USA.
Jason I HerschkowitzDepartment of Biomedical Sciences, Cancer Research Center, University at Albany, State University of New York, Rensselaer, NY 12222, USA.
Maria HepelDepartment of Chemistry, State University of New York at Potsdam, Potsdam, NY 13676, USA.ORCID 0000-0002-8127-8260
University at Albany, State University of New York · USInLife Institute of Animal Reproduction and Food Research, Polish Academy of Sciences · PLState University of New York at Potsdam · US

Funding

State University of New York Network of Excellence 1-114-594
6 · The paper itself

Abstract

The interactions of chemotherapeutic drugs with nanocage protein apoferritin (APO) are the key features in the effective encapsulation and release of highly toxic drugs in APO-based controlled drug delivery systems. The encapsulation enables mitigating the drugs' side effects, collateral damage to healthy cells, and adverse immune reactions. Herein, the interactions of anthracycline drugs with APO were studied to assess the effect of drug lipophilicity on their encapsulation excess

Indexed as

AnthracyclinesAntibiotics, AntineoplasticApoferritinsCell Line, TumorDaunorubicinDelayed-Action PreparationsDoxorubicinDrug Delivery SystemsEpirubicinHeLa CellsHumansHydrophobic and Hydrophilic InteractionsNanostructuresNeoplasmsAnthracyclinesAntibiotics, AntineoplasticApoferritinsDaunorubicinDelayed-Action PreparationsDoxorubicinEpirubicinanthraquinone drugs’ hydrophobic interactionsapoferritin model calculationsapoferritin nanocarrierscontrolled drug deliverydrug-nanocage interactionsferritin receptor targetingfolate receptor targetingidarubicin

Identifiers

PMID33572999
PMCPMC7866407
OpenAlexW3128607978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.